MX2020010675A - Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina. - Google Patents
Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.Info
- Publication number
- MX2020010675A MX2020010675A MX2020010675A MX2020010675A MX2020010675A MX 2020010675 A MX2020010675 A MX 2020010675A MX 2020010675 A MX2020010675 A MX 2020010675A MX 2020010675 A MX2020010675 A MX 2020010675A MX 2020010675 A MX2020010675 A MX 2020010675A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolo
- triazine
- pyrimidine derivatives
- diseases
- dependent kinase
- Prior art date
Links
- RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical compound N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina y/o sales farmacéuticamente aceptables de los mismos, al uso de estos derivados como agentes farmacéuticamente activos, especialmente para la profilaxis y/o tratamiento de enfermedades proliferativas celulares, enfermedades inflamatorias, enfermedades inmunológicas, enfermedades cardiovasculares y enfermedades infecciosas. Además, la presente invención está dirigida a composiciones farmacéuticas que contienen al menos uno de los derivados de pirazolo[1,5-a][1,3,5]triazina y pirazolo[1,5-a]pirimidina y/o sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656070P | 2018-04-11 | 2018-04-11 | |
| PCT/EP2019/059302 WO2019197549A1 (en) | 2018-04-11 | 2019-04-11 | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010675A true MX2020010675A (es) | 2020-10-28 |
Family
ID=66334385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010675A MX2020010675A (es) | 2018-04-11 | 2019-04-11 | Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11945822B2 (es) |
| EP (1) | EP3774810A1 (es) |
| JP (2) | JP2021521120A (es) |
| KR (1) | KR20200141487A (es) |
| CN (1) | CN112313235A (es) |
| AU (1) | AU2019250507B2 (es) |
| BR (1) | BR112020020768A2 (es) |
| CA (1) | CA3095880A1 (es) |
| IL (1) | IL277770B2 (es) |
| MX (1) | MX2020010675A (es) |
| PH (1) | PH12020551639A1 (es) |
| SG (1) | SG11202009724YA (es) |
| WO (1) | WO2019197549A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020186196A1 (en) * | 2019-03-13 | 2020-09-17 | The Translational Genomics Research Institute | Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors |
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| JP2023507028A (ja) | 2019-12-20 | 2023-02-20 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 複素環式化合物とその医薬組成物、調製方法、中間体及び使用 |
| EP4114528A1 (en) * | 2020-03-06 | 2023-01-11 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
| CN112079781B (zh) * | 2020-09-30 | 2022-11-22 | 苏州康润医药有限公司 | 5-溴-1-甲基-1h-吡唑-3-胺的合成方法 |
| EP4255909A1 (en) * | 2020-12-02 | 2023-10-11 | Qurient Co. Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
| GB202108572D0 (en) * | 2021-06-16 | 2021-07-28 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| CN114195710A (zh) * | 2021-12-20 | 2022-03-18 | 上海彩迩文生化科技有限公司 | 一种喹啉类胺甲基化合物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP2009007342A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2634189A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2634190A1 (en) | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2015240518A1 (en) | 2014-04-05 | 2016-10-20 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| JP6789962B2 (ja) | 2015-03-09 | 2020-11-25 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体 |
| WO2019144149A2 (en) * | 2018-01-22 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Treatment methods for pancreatic tumors associated with the worst prognosis |
-
2019
- 2019-04-11 EP EP19720425.8A patent/EP3774810A1/en active Pending
- 2019-04-11 US US17/045,030 patent/US11945822B2/en active Active
- 2019-04-11 KR KR1020207032379A patent/KR20200141487A/ko unknown
- 2019-04-11 JP JP2020555100A patent/JP2021521120A/ja active Pending
- 2019-04-11 AU AU2019250507A patent/AU2019250507B2/en active Active
- 2019-04-11 CN CN201980039582.5A patent/CN112313235A/zh active Pending
- 2019-04-11 SG SG11202009724YA patent/SG11202009724YA/en unknown
- 2019-04-11 CA CA3095880A patent/CA3095880A1/en active Pending
- 2019-04-11 MX MX2020010675A patent/MX2020010675A/es unknown
- 2019-04-11 WO PCT/EP2019/059302 patent/WO2019197549A1/en active Application Filing
- 2019-04-11 BR BR112020020768-3A patent/BR112020020768A2/pt unknown
- 2019-04-11 IL IL277770A patent/IL277770B2/en unknown
-
2020
- 2020-10-05 PH PH12020551639A patent/PH12020551639A1/en unknown
-
2023
- 2023-08-14 JP JP2023131904A patent/JP2023138858A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3095880A1 (en) | 2019-10-17 |
| JP2021521120A (ja) | 2021-08-26 |
| US11945822B2 (en) | 2024-04-02 |
| AU2019250507A1 (en) | 2020-10-22 |
| AU2019250507B2 (en) | 2023-09-28 |
| IL277770B1 (en) | 2023-09-01 |
| SG11202009724YA (en) | 2020-10-29 |
| US20210147427A1 (en) | 2021-05-20 |
| BR112020020768A2 (pt) | 2021-01-19 |
| EP3774810A1 (en) | 2021-02-17 |
| JP2023138858A (ja) | 2023-10-02 |
| PH12020551639A1 (en) | 2021-07-05 |
| IL277770A (en) | 2020-11-30 |
| WO2019197549A1 (en) | 2019-10-17 |
| CN112313235A (zh) | 2021-02-02 |
| IL277770B2 (en) | 2024-01-01 |
| KR20200141487A (ko) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551639A1 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
| PH12020551638A1 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| MX347359B (es) | Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| NZ766835A (en) | Pharmaceutical compounds | |
| CR20200441A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| MD4735C1 (ro) | Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK) | |
| MX2016007371A (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
| EP4072548A4 (en) | COMPOSITIONS AND METHODS FOR SUBSTITUTED 7-(PIPERAZINE-1-YL)PYRAZOLO[ 1,5-A]PYRIMIDINE ANALOGUES AS INHIBITORS BY KRAS | |
| MX368162B (es) | Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr). | |
| MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
| ZA202205900B (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer | |
| MX2021004487A (es) | Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| MX2022002219A (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
| MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| NZ630580A (en) | 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer | |
| MX2021004769A (es) | Compuestos, composiciones, y metodos para modular la actividad cdk9. | |
| MX2021016149A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
| WO2021074620A9 (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| MX2018004517A (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. |